tiprankstipranks
Trending News
More News >

Paradigm Biopharmaceuticals Announces Proposed Securities Issue

Story Highlights
Paradigm Biopharmaceuticals Announces Proposed Securities Issue

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Paradigm Biopharmaceuticals ( (AU:PAR) ) is now available.

Paradigm Biopharmaceuticals Limited has announced a proposed issue of 8,000,000 ordinary fully paid securities. This move is part of a placement or other type of issue, which is expected to impact the company’s capital structure and potentially enhance its market position by providing additional financial resources for its operations and strategic initiatives.

The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on developing and commercializing therapies for various medical conditions. The company is known for its work in repurposing existing drugs to treat new indications, with a particular emphasis on inflammatory diseases and pain management.

Average Trading Volume: 872,229

Technical Sentiment Signal: Sell

Current Market Cap: A$124.6M

See more insights into PAR stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1